Ephraim Fuchs, MD
Medical Oncology · Baltimore, MDNPI 1578506135
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. That places this record below the midpoint for medical oncology clinicians in MD, where the typical reported total is $4,199.
Across 3 payments — averaging $1324.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$2K
- One Lambda, Inc.$2K
Across 6 payments — averaging $34,113 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$139K
- Pharmacyclics LLC, An Abbvie Company$66K
What the payments were for
- Consulting fees$2,12053%
- Travel & lodging$1,21731%
- Food & beverage$63816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 1 | $2,120 |
| One Lambda, Inc. | 2 | $1,855 |
How this compares
$3,975 in reported general payments places this provider in the 45th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JaypircaPirtobrutinib | 19 | $405,099 |
| ImbruvicaIbrutinib | 12 | $325,988 |
| BrukinsaZanubrutinib | 19 | $289,399 |
| RevlimidLenalidomide | 13 | $219,835 |
| ValacyclovirValacyclovir Hcl | 19 | $1,355 |
| Prochlorperazine Maleate | 13 | $116 |
| Oxycodone Hcl | 13 | $100 |
| Prednisone | 40 | $99 |
| Ondansetron Hcl | 13 | $42 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.